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ORIGINAL RESEARCH

Acceptability of Behavioral Treatments
for Insomnia
Daniel Bluestein, MD, MS, CMD, AGSF, Amanda C. Healey, PhD, LPC-MHSP, NCC,
and Carolyn M. Rutledge, PhD, FNP-BC
Background: Behavioral treatments for insomnia are safe and efficacious but may not be embraced by
patients in primary care. Understanding factors associated with acceptability can enhance successful use
of these modalities. The objective of this study was to identify demographic and clinical/psychosocial
correlates of behavioral insomnia treatment acceptability.
Methods: This nonexperimental, inventory-based, cross-sectional study enrolled patients from a hospital-sponsored primary care clinic and 2 urban academic family practices. Participants (n ⴝ 236) were
18 years of age or older who had clinically significant insomnia (Insomnia Severity Index score > 8)
and were recruited consecutively at these sites. A study coordinator obtained informed consent then
distributed survey materials. Participants received a $10 honorarium. The main outcome measure was
the Acceptability Insomnia Treatment Acceptability Scale-Behavioral subscale (ITAS-B).
Results: Only acceptability of medications (r ⴝ 0.259) and dysfunctional beliefs (r ⴝ 0.234) scores
had significant bivariate correlations with ITAS-B scores (P < .001). Medication acceptability, dysfunctional beliefs, and self-efficacy accounted for 12.45% of ITAS-B variance in linear regression.
Conclusions: Screening for dysfunctional beliefs about sleep may identify patients with interest in
behavioral approaches. Improving self-efficacy for sleep may improve acceptance of behavioral insomnia therapies. Interest in behavioral and medication treatments are not mutually exclusive. However,
the modest variance reported here suggests other factors impact acceptance of behavioral treatments.
(J Am Board Fam Med 2011;24:272–280.)
Keywords: Insomnia, Patient Acceptance of Health Care, Primary Health Care

Primary care clinicians prioritize disorders that are
common, costly, and severe. Placed in this perspective, insomnia is an important primary care concern.1 An estimated 40 to 70 million Americans are
affected with insomnia intermittently, and 10% to
20% have chronic insomnia.2 Insomnia costs ex-
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ceed $42 billion each year.3 Consequences include
mood disturbances, medication habituation, memory impairment, daytime fatigue, vocational and
interpersonal difﬁculties, increased health care utilization, impaired health status,4 – 6 and accidents.7
Insomnia is often treated with hypnotic medications,8 Although indicated for the short term,9
medication usage may become chronic.10 –12 Sedation, abuse, physical and psychological dependence,
rebound insomnia,13 falls, and motor vehicle accidents14,15 are potential sequelae. Newer agents
have less abuse potential16 but are costly ($100 to
$150 per month)17,18 and predispose the individual
to daytime sedation, psychological habituation, and
accidents.19
Concerns about drug treatments have fostered
interest among primary care clinicians in behavioral interventions for insomnia. Evidence-based
techniques include stimulus control, relaxation,
sleep restriction, paradoxical intent, sleep hygiene,
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and cognitive-behavioral therapy.20,21 Compared
with medications, which are symptomatic treatments, behavioral approaches lead to sustained
beneﬁt because they address perpetuating behaviors and beliefs.22 Further advantages compared
with medications include no known side effects.
Nonetheless, patients may not embrace behavioral treatments. Some may perceive receiving a
behavioral treatment as evidence of having a psychiatric disorder. Such views may be associated
with poverty, lack of formal education, and racial or
ethnic minority status,23–25 perhaps because stigmatization of treatments for “mental illness” is
more likely among these groups.26 –29 Conversely,
demographic predictors of acceptance include female sex and higher educational attainment.30 Effects of age are unclear; some studies show positive
orientation and others negative.31
Behavioral treatments also require effort from a
motivated patient. Several clinical and psychosocial
variables may impact this motivation. Impaired
health status has been shown to forecast drop-out
from behavioral treatment programs for insomnia.32 Depression has been identiﬁed with reduced
adherence and impaired response to cognitive-behavioral therapy for insomnia.33 Self-efﬁcacy for
sleep is another potential predictor because high
self-efﬁcacy predicts readiness to undertake behavioral change, whereas low self-efﬁcacy points to a
lack of readiness to take action.34 Distorted beliefs
and attitudes concerning insomnia may accentuate
anxiety about not sleeping, and thus patients desire
rescue by medications.35 Insomnia severity has potential import as a mediator of the urgency of
help-seeking.36,37
It is not known which of these demographic and
clinical/psychosocial predictors have greatest salience. Understanding which are most strongly associated with acceptability, or its lack, can enhance
successful use of behavioral treatments. Speciﬁcally, knowing how relationships vary across sociodemographic subgroups can direct educational
interventions toward groups with lower interest.
Preferences for drug therapy would suggest a need
for education about risks and beneﬁts of drugs as
well as the availability of nondrug alternatives. If
poor health status predicts low interest, then selfrated health or other short health status questionnaires could screen for readiness to use behavioral
modalities. Depression, if predominant, can be
treated before or concurrently with the introduc-
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tion of behavioral insomnia approaches. Motivational interviewing strategies would be indicated
should low self-efﬁcacy be a net predictor of low
acceptance. Elicitation of dysfunctional beliefs and
attitudes about sleep may inform educational approaches. If insomnia severity mediates acceptance,
then assessment of severity could help select patients who are motivated to use behavioral or mixed
treatment modalities. Accordingly, this study was
undertaken to identify individual and net demographic and clinical/psychosocial correlates of behavioral insomnia treatment acceptability among
primary care patients.

Methods
Design
This nonexperimental, inventory-based, cross-sectional study assessed relationships between the willingness to engage in behavioral intervention for the
treatment of insomnia and demographic factors,
acceptability of medications, health status, depression, self-efﬁcacy for sleep, dysfunctional beliefs
about sleep, and insomnia severity. Methods for
this study closely parallel those detailed in a related
article concerning psychosocial correlates of insomnia severity, which was previously published in
The Journal of the American Board of Family Medicine.38 Accordingly, key elements are summarized
here, as are details about measures of treatment
acceptability, which were not reported previously.
Participants
Participants were recruited consecutively from patients 18 years of age or older who were seen for
care (any reason; not conﬁned to seeking care for
sleep problems) at 3 clinical sites. These included a
hospital-sponsored primary care clinic (site 1) and 2
urban, academic family practice centers (sites 2 and
3). The study was advertised by ﬂyers posted in
waiting rooms and examination rooms. Exclusionary criteria included being younger than 18, being
illiterate, or lacking the cognitive capacity to complete informed consent or respond to surveys. Inclusion criteria entailed being age 18 or older and
having clinically signiﬁcant insomnia, as indicated
by a score of ⱖ8 on the Insomnia Severity Index
(ISI). This is a 7-item questionnaire that asks respondents to rate severity of recent problems with
sleep onset, sleep maintenance, early waking, and
impact of insomnia using a 5-point Likert scale
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(0 ⫽ not at all, 4 ⫽ extremely). ISI scores may
range from 0 to 28. Higher scores indicate more
severe insomnia, within 4 categories: absence of
insomnia (0 –7), mild insomnia (8 –14), moderate
insomnia (15–21), and severe insomnia (22–28).39
Data Collection
After the approval of the study by the institutional
review board, a study coordinator (ACH) obtained
informed consent then distributed survey packets
to participants. Surveys took between 20 to 30
minutes to complete. The coordinator was available to provide clariﬁcation if requested. Participants received a $10 cash honorarium after completion. Surveys were then stored without names or
other means of personal identiﬁcation. Data were
entered and stored in a secure, password-protected
database accessible only to members of the research
team.
Measures
Treatment preferences were measured using the
Insomnia Treatment Acceptability Scale (ITAS).40
The ITAS describes 2 equally effective treatment
options. The ﬁrst is a nondrug treatment method
aimed at teaching self-management approaches to
improving sleep. The other is a new medication (no
drug is named) to reduce physiologic and cognitive
arousal and to reduce nighttime awakening. Respondents rate each treatment on identically worded,
8-item subscales (behavioral [ITAS-B] and medication [ITAS-M]), both of which are scored by visual
analog on a 100-mm line. Total score for each subscale is the average of the 8 items, with higher scores
indicating greater willingness to utilize the treatment. Reported Cronbach’s ␣ values for the
ITAS-B and ITAS-M range from 0.80 to 0.87,
respectively.41,42 In this study, the Cronbach’s ␣
values were similar, being 0.859 and 0.861 for the
ITAS-B and ITAS-M, respectively. The ITAS-B is
used in this study to assess the outcome variable
(acceptability of behavioral sleep interventions).
The ITAS-M measures acceptability of medications as a potential predictor of behavioral acceptability.
Measured sociodemographic variables included
age, sex, race, marital status, and education. All
were assessed by a researcher-designed survey. Age
was measured as ratio (continuous) level data. Sex,
race, marital status, and educational level were categorical. Health status was measured with the
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8-item Short Form (SF-8)43; depressive symptoms
were measured with the Center for Epidemiologic
Studies-Depression scale (CES-D)44; self-efﬁcacy
was measured with the Self-Efﬁcacy for Sleep scale
(SE-S)45; dysfunctional beliefs regarding sleep were
measured with the Dysfunctional Beliefs about
Sleep (DBAS) scale46,47; and insomnia severity was
measured with the ISI, as discussed above48 Reliability and validity of these measures is detailed in
our earlier report.38
Statistical Analyses
Statistical analyses ﬁrst entailed characterization of
participants using descriptive and summary statistics
(mean and SD for continuous variables; percentages
for categorical variables). Individual associations
with behavioral acceptability were examined using Pearson correlation coefﬁcients for continuous data and Spearman correlation coefﬁcients for
ordinal data. All variables were screened for normality
before conducting analysis. Means were imputed for 5
cases that had less than 2 missing values on the
CES-D. Step-wise linear regression was then conducted to provide an exploratory examination regarding acceptability of medications, health status, depression, self-efﬁcacy, dysfunctional beliefs, and insomnia
severity as net predictors of acceptability of behavioral
treatments.

Results
There were 236 participants: 163 from site 1, 56 from
site 2, and 17 from site 3. As shown in Table 1, mean
age was 45 years (range, 19 –91 years), with 221
participants reporting. Participants were 74%
women (n ⫽ 236), 74% African American (n ⫽
160), and 36% were married (n ⫽ 236). Of 235
participants reporting educational level, 64% reported a high school education, 17% were college
graduates, and 19% reported postgraduate education. Ten percent (30 participants) were age ⱖ65
years.
To obtain a signiﬁcant effect size to achieve a
power level ⱖ0.80 while detecting at least a moderate level of difference between correlated variables, an N ⫽ 125 would be necessary to achieve
␣ ⫽ 0.01.49 This number was exceeded here, ensuring adequate power to achieve practical signiﬁcance.
Table 2 reports means and SDs for the behavioral
treatment acceptability and psychosocial predictors
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Table 1. Demographic Information

Age, years (n ⫽ 236)
Mean
Range
Sex (n ⫽ 236)
Male
Female
Ethnicity (n ⫽ 160)
African American
White
Asian
Hispanic
Other
Relationship status (n ⫽ 236)
Married
Widowed
Never married
Divorced
Level of education (n ⫽ 235)
Some high school
High school graduate
College graduate
Professional/graduate

All Sites

Site 1

Site 2

Site 3

45
19–91

45
19–83

44
20–68

45
22–91

61 (26)
175 (74)

45 (28)
118 (72)

16 (29)
40 (71)

1 (6)
16 (94)

119 (74)
34 (21)
2 (1)
1 (0.5)
4 (2.5)

101 (73)
26 (20)
1 (1)
1 (1)
4 (3)

6 (60)
3 (30)
0 (0)
1 (10)
0 (0)

12 (71)
5 (29)
0 (0)
0 (0)
0 (0)

84 (36)
17 (7)
73 (31)
62 (26)

56 (34)
11 (7)
52 (32)
44 (27)

19 (34)
5 (9)
18 (32)
14 (25)

9 (52)
1 (6)
3 (18)
4 (24)

43 (18)
107 (46)
40 (17)
45 (19)

34 (21)
70 (43)
26 (16)
32 (20)

8 (14)
27 (48)
10 (18)
11 (20)

1 (6)
10 (58)
4 (24)
2 (12)

Values provided as n (%), except for Age, which is presented as number of years.

according to site. The mean for behavioral acceptability indicated above-average interest (ITAS-B mean,
0.65; range, 0.13–1.0), as did the mean for medication
acceptability (ITAS-M mean, 0.63; range, 0.04 –
0.98). Means for psychosocial predictors were midrange for health status (SF-8 mean, 24; range, 8 – 42);
depression (CES-D mean, 22; range, 0 – 49); dysfunctional beliefs and attitudes about sleep
(DBAS mean, 0.50; range, 0.06 – 0.94); self-efﬁcacy (SE-S mean, 23; range, 9 – 45); and insomnia
severity (ISI mean, 17; range, 8 –29).

As noted in Tables 1 and 2, there is no signiﬁcant variation by site with regard to sociodemographic attributes and means for the ITAS-B, ISI,
SF-8, CES-D, DBAS, and SE-S. Accordingly, data
were pooled for the subsequent regression analysis.
Table 3 reports individual correlation coefﬁcients for independent variables with ITAS-B
scores (behavioral treatment acceptability). Spearman coefﬁcients were computed for categorical
variables (sex, ethnicity, relationship status). Pearson coefﬁcients were computed for interval/ratio

Table 2. Means and Standard Deviations for Behavioral Acceptability and Psychosocial Predictors

ITAS-B
ITAS-M
SF-8
CES-D
SE-S
DBAS
ISI

Total

Site 1

Site 2

Site 3

0.65 (0.18)
0.63 (0.18)
24 (6.8)
22 (11.2)
23 (7.2)
0.50 (0.15)
17 (5.4)

0.65 (0.20)
0.63 (0.18)
24 (6.9)
22 (11.2)
24 (7.4)
0.51 (0.16)
16 (5.4)

0.67 (0.18)
0.70 (0.15)
24 (6.7)
23 (11.6)
22 (6.1)
0.50 (0.14)
20 (4.2)

0.66 (0.16)
0.61 (0.19)
23 (6.2)
24 (9.8)
22 (8.9)
0.52 (0.14)
17 (7.2)

ITAS-B, Insomnia Treatment Acceptability Scale–Behavioral Subscale; ITAS-M, Insomnia Treatment Acceptability Scale–Medication Subscale; SF-8, Medical Outcomes Study SF-8 global health status measure; CES-D, Center for Epidemiologic Studies
Depression Scale, SE-S, Self-Efﬁcacy for Sleep Scale; DBAS, Dysfunctional Beliefs about Sleep Scale; ISI, Insomnia Severity Index.
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Table 3. Correlations with Insomnia Treatment
Acceptability Scale–Behavioral Subscale Scores
Predictors

r

Demographic
Sex
Age
Ethnicity
Relationship status
Education
Psychosocial
ITAS-M*
SF-8
CES-D
SE-S
DBAS*
ISI

⫺0.074
⫺0.053
0.005
0.034
⫺0.027
0.259
0.017
0.121
0.053
0.234
0.099

*P ⬍ .001.
ITAS-M, Insomnia Treatment Acceptability Scale–Medication
Subscale; SF-8, Medical Outcomes Study SF-8 global health
status measure; CES-D, Center for Epidemiologic Studies Depression Scale, SE-S, Self-Efﬁcacy for Sleep Scale; DBAS, Dysfunctional Beliefs about Sleep Scale; ISI, Insomnia Severity
Index.

variables (age, medication acceptability [ITAS-M],
health status [SF-8], depression [CES-D], self-efﬁcacy for sleep [SE-S], dysfunctional beliefs and attitudes about sleep [DBAS], and insomnia severity
[ISI]). There were no signiﬁcant associations between
behavioral treatment acceptability and sociodemographic status. With regard to psychosocial predic-

tors, acceptability of medication treatment (ITAS-M;
r ⫽ 0.259) and dysfunctional belief (DBAS; r ⫽
0.234) scores were both signiﬁcantly correlated
with behavioral treatment acceptability scores (P ⬍
.001).
Linear regression models were examined to determine net predictors of behavioral treatment acceptability. Inclusion of demographic variables explained
0.2% of ITAS-B variance (r2 ⫽ 0.002) and was not
statistically or practically signiﬁcant in a step-wise
regression analysis; hence these factors were not considered further. Interrelationships of psychosocial
predictors required further exploration. A simple linear regression was used to determine the contribution
of each psychosocial factor. Medication acceptability
had the strongest bivariate association with behavioral
acceptability. However, medication acceptability also
was strongly related to other psychosocial predictors.
Accordingly, regression models without (Table 4) and
with (Table 4) medication acceptance were examined.
The model excluding medication preference explained 9.3% of the variance in ITAS-B scores. In this
model, both dysfunctional beliefs and self-efﬁcacy for
sleep explained strong net associations with behavioral acceptability (P ⬍ .001). Insomnia severity was
also signiﬁcantly associated with behavioral treatment
acceptability at a P ⬍ .05 signiﬁcance level. Medication acceptance emerged as the strongest single net
predictor of behavioral treatment acceptability, explaining 8.4% of variance in ITAS-B scores. When

Table 4. A: Initial Regression Analysis for Behavioral Treatment Acceptability and Regression Analysis for
Behavioral Treatment Acceptability Including Medication Acceptability

Initial regression analysis for BTA
Linear model
Dysfunction beliefs
SE-S
ISI
Regression analysis for BTA including
medication acceptability
ITAS-M model
Final model
Dysfunction beliefs
SE-S
ITAS-M

R2

F

Adjusted R2

0.113

5.833

0.093

0.088
0.135

22.596
12.074

0.084
0.124

␤

P

0.319
0.006
0.005

⬍.001
⬍.001
⬍.05

0.277

⬍.001

0.252
0.004
0.229

⬍.002
⬍.01
⬍.001

The ISI, SF-8 and CES-D were included in the analysis but were excluded from the ﬁnal model because of nonsigniﬁcant contribution
to overall predictive power.
BTA, behavioral treatment acceptability; ITAS-M, Insomnia Treatment Acceptability Scale–Medication Subscale; SE-S, Self-Efﬁcacy
for Sleep Scale; ISI, Insomnia Severity Index.
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medication acceptance was included as a predictor,
insomnia severity was no longer a signiﬁcant factor in
the model, possibly because of the signiﬁcant correlation between ITAS-M results and insomnia severity, as measured by the ISI (r ⫽ 0.249; P ⬍ .001). The
combination of preference for medication, dysfunctional beliefs about sleep, and self-efﬁcacy for sleep
created a best model at F(3, 235) ⫽ 12.074 (P ⬍ .001),
accounting for 12.45% of the construct variance. Depression scores and health status were included in
both models (Table 4) but made no signiﬁcant contribution to overall predictive power.

Discussion
This study was conducted to identify demographic
and clinical/psychosocial correlates of acceptance
of behavioral treatments for insomnia. Our results
do not reveal any demographic associations with
behavioral treatment acceptance. Acceptance of
medications emerged as the strongest net predictor. Insomnia severity, depressive symptoms, and
concurrent poor health status were not predictive.
However, the presence of high self-efﬁcacy for
sleep-inducing behavior and dysfunctional beliefs
and attitudes about sleep (anxiety over the perceived consequences of poor sleep, lack of information about insomnia causes and treatment, and unrealistic expectations of treatment) were signiﬁcant
net predictors of behavioral acceptance.
Together, these variables accounted for 12.45%
of variance in behavioral treatment acceptance.
Other unmeasured variables may explain behavioral treatment acceptance, and full understanding
of acceptance determinants cannot be offered at
this time. Nonetheless, in psychosocial research,
wherein numerous factors inﬂuence behavior, beliefs, and preferences, variance accounted for at this
level is considered substantive.49
Lack of demographic associations indicates, ﬁrst,
that there is no signiﬁcant need to target disinterested
groups for education regarding the beneﬁts of behavioral treatments. In addition, neither educational attainment nor race/ethnicity had associations with behavioral acceptance. Thus, lower education and
minority status—factors associated with resistance to
behavioral and psychological treatments in other contexts— did not predict resistance to (nonacceptance
of) behavioral insomnia treatments. Providers should
avoid stereotypic treatment decisions by assuming
disinterest based on sociodemographic attributes.
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The strong net relationship between behavioral
and medication acceptance is perhaps a function of
insomnia severity, which is highly correlated with
medication preference. In other words, patients more
severely impacted by their lack of sleep may be more
open to both options or to the rapid relief that medications can afford. This relationship also may reﬂect
the characteristics of patients seen in primary care
medical settings, who are accustomed to medical and
medication solutions for many problems. Acceptance
of both behavioral treatments and medications is both
surprising and informative. The historic separation of
mind and body in health care can lead clinicians to
view behavioral and medication modalities as opposites and that interest in one implies disinterest in the
other. However, our ﬁndings indicate that patients
presenting with requests for quick relief from sleeping
pills, a typical primary care scenario, should not be
presumed to be unaccepting of the longer-term advantages offered by behavioral treatments.
Depression and concomitant poor health status
did not predict behavioral acceptance. Assessment
of depression and medical/medication contributors
remains a key part of insomnia assessment and
diagnosis but, based on these results, should not be
used to assess patient acceptance of treatment recommendations.
The ﬁnding that self-efﬁcacy for sleep is related
to interest in behavioral treatments indicates that
self-efﬁcacy should be enhanced if behavioral treatments are to be accepted and successful. Thus,
self-efﬁcacy should be examined during the course
of developing an insomnia treatment plan and fostered, if necessary, using techniques such as motivational interviewing.
The relationship between behavioral treatment acceptance and dysfunctional beliefs suggests that eliciting the latter might be used to identify persons who
are open to behavioral approaches. This screening
can be accomplished easily in practice during the
course of eliciting a history of the insomnia complaint. Alternatively, the DBAS measure used in this
study could be used. A shorter, 16-item version recently has been validated.50
Several potential limitations need to be acknowledged in a discussion of these results. First, data were
collected at 3 separate sites. Comparison of results by
site reveals no observable differences, but unrecognized biases may have impacted results. Second, biases resulting from misunderstanding of survey items
or erroneous or falsiﬁed responses may have impacted
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results. Third, incomplete reporting of ethnicity may
have obscured relationships between race and insomnia severity. Nonetheless, the study sample was predominantly women and African Americans, attributes
that may limit generalizability. On the other hand,
this predominantly African-American sample advances understanding of treatment preferences
among a group at risk for greater insomnia severity
and consequences.51 Fourth, the $10 reimbursement
for survey completion may have motivated persons
without insomnia and thus no true treatment preferences to inﬂate ISI scores to qualify. Fifth, the crosssectional design reveals associations but not cause and
effect between treatment acceptance and hypothesized predictors. In addition, patients’ statements of
preference may not actually translate to following
through with a treatment option. Finally, despite the
signiﬁcant predictive power of medication preference,
self-efﬁcacy, and dysfunctional beliefs and attitudes
about sleep, these variables accounted for 12.45% of
variance in behavioral treatment acceptance. Other
unmeasured variables also are explanatory and should
be examined in future research. Such variables may
include anxiety or health beliefs. Quality of the relationship with the health care provider is another potential explanatory factor because satisfaction with
communication predicts treatment adherence and
thus greater likelihood of efﬁcacy.52

Conclusion
This study identiﬁes acceptance of medication
treatment, self-efﬁcacy of sleep-inducing behaviors, and the presence of dysfunctional beliefs and
attitudes about sleep as predictors of acceptance of
behavioral treatments for insomnia, although other
unmeasured factors are also important contributors. Compared with previous studies of treatment
preferences, which were conducted mainly among
patients who were engaged in behavioral treatment
trials, this study was conducted in primary care, to
which most insomnia patients present and where
there is not a priori interest in behavioral treatments. Although our results are cross-sectional and
therefore preliminary, they are potentially relevant
to clinicians in several respects. First, providers
should not assume that patients who present with
requests for quick relief using sleeping pills are disinterested in behavioral treatments. Second, assessing
and facilitating self-efﬁcacy for sleep-enhancing behavioral change potentially can improve readiness for
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and acceptance of behavioral insomnia therapies. Finally, screening for dysfunctional beliefs and attitudes
about sleep can identify patients who have interest in
behavioral approaches. Future research using prospective research designs, a broader range of explanatory variables is needed to conﬁrm these ﬁndings
and to examine relationships to satisfaction with care,
improvement in sleep quality and insomnia severity,
and patient-centered clinical outcomes such as wellbeing and daytime function.

References
1. NIH State-of-the-Science Conference Statement on
manifestations and management of chronic insomnia
in adults. NIH Consens State Sci Statements 2005;
22(2):1–30.
2. Trans-NIH Sleep Research Coordinating Committee,
US Department of Health and Human Services. National Institute of Health. 2003 national sleep disorders research plan. Available at: http://www.nhlbi.
nih.gov/health/prof/sleep/res_plan/sleep-rplan.pdf.
Accessed March 30, 2011.
3. Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and management of chronic insomnia in adults.
Evid Rep Technol Assess (Summ) 2005;(125):1–10.
4. Silber MH. Clinical practice. Chronic insomnia.
N Engl J Med 2005;353(8):803–10.
5. Katz DA, McHorney CA. The relationship between
insomnia and health-related quality of life in patients
with chronic illness. J Fam Pract 2002;51:229 –35.
6. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbances and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry
1996;39:411– 8.
7. Costa E, Silva JA, Chase M, Sartorius M, Roth T.
Special report from a symposium held by the World
Health Organization and the World Federation of
Sleep Research Societies: an overview of insomnias
and related disorders—recognition, epidemiology,
and rational management. Sleep 1996;19:412– 6.
8. Morin CM, Wooten V. Psychological and pharmacological approaches to treating insomnia. Clin Psychol Rev 1996;16:521– 42.
9. Kirkwood CK. Management of insomnia. J Am
Pharm Assoc (Wash) 1999;39(5):688 –96.
10. Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care.
Gen Hosp Psychiatry 2006;28(5):374 – 8.
11. Ohayon MM, Caulet M. Psychotropic medication
and insomnia complaints in two epidemiological
studies. Can J Psychiatry 1996;41:457– 64.
12. Holbrook AM, Crowther R, Lotter A, Cheng C,
King D. Meta-analysis of benzodiazepine use in the
treatment of insomnia. CMAJ 2000;162:225–33.
13. Wilson SJ, Nutt DJ. Treatment of insomnia. Psychiatry 2007;6:301– 4.

http://www.jabfm.org

14. Morin CM, Bastien C, Guay B, Radouco-Thomas
M, Leblanc J, Vallieres A. Randomized clinical trial
of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in
older adults with chronic insomnia. Am J Psychiatry
2004;161:332– 42.
15. Englert S, Linden M. Differences in self-reported
sleep complaints in elderly persons living in the community who do or do not take sleep medication.
J Clin Psychiatry 1998;59:137– 44.
16. National Institute for Clinical Excellence. Guidance
for the use of zaleplon, zolpidem and zopiclone for the
short-term management of insomnia. Technology
appraisal 77. Available at: http://www.nice.org.uk/
nicemedia/pdf/TA077fullguidance.pdf. Accessed
24 August 2010.
17. Drugstore.com, Inc. Available at: http://www.
drugstore.com [homepage]. Accessed 24 August
2010.
18. Ward CR. Ramelteon (Rozerem) for insomnia. Am
Fam Physician 2006;73(8):1437.
19. Cimolai N. Zopiclone: is it a pharmacologic agent
for abuse? Can Fam Physician 2007;53(12):2124 –9.
20. Morgenthaler T, Kramer M, Alessi C, et al. Practice
parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of
Sleep Medicine report. Sleep 2006;29(11):1415–9.
21. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie
CA, Lichstein KL. Psychological and behavioral treatment of insomnia: update of the recent evidence
(1998 –2004). Sleep 2006;29(11):1398 – 414.
22. Morin CM. Combined therapeutics for insomnia:
Should our ﬁrst approach be behavioral or pharmacological? Sleep Med 2006;7(Suppl 1):S15–9.
23. Nadeem E, Lange JM, Edge D, Fongwa M, Belin T,
Miranda J. Does stigma keep poor young immigrant
and US-born Black and Latina women from seeking
mental health care? Psychiatr Serv 2007;58(12):1547–54.
24. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Rockville,
MD: US Department of Health and Human Services,
Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; 2000.
25. Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 2001;158(3):479 – 81.
26. Cooper-Patrick L, Powe NR, Jenckes MW, Gonzales JJ, Levine DM, Ford DE. Identiﬁcation of patient
attitudes and preferences regarding treatment of depression. J Gen Intern Med 1997;12:431– 8.
27. Sirey JA, Bruce ML, Alexapoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 2001;75:479 – 81.
28. Klap R, Unroe KT, Unutzer J. Caring for mental
illness in the United States: a focus on older adults.
Am J Geriatr Psychiatry 2003;11(5):517–24.

doi: 10.3122/jabfm.2011.03.100246

29. Skultety KM. An investigation of mental health service utilization by older adults. Dissertation Abstracts International, Section B: The Sciences & Engineering. 2004;64(10-B):5234.
30. Morin CM, Gaulier B, Barry T, Kowatch RA. Patients’
acceptance of psychological and pharmacological therapies for insomnia. Sleep 1992;15(4):302–5.
31. Morin CM, Hauri PJ, Espie CA, Spielman AJ,
Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of
Sleep Medicine review. Sleep 1999;22(8):1134 –56.
32. Morgan K, Thompson J, Dixon S, Tomeny M,
Mathers N. Predicting longer-term outcomes following psychological treatment for hypnotic-dependant
chronic insomnia. J Psychosom Res 2003;54(1):21–9.
33. Vincent NK, Hameed H. Relation between adherence and outcome in the group treatment of insomnia. Behav Sleep Med 2003;1(3):125–39.
34. Bouchard S, Bastien C, Morin CM. Self-efﬁcacy and
adherence to cognitive-behavioral treatment of insomnia. Behav Sleep Med 2003;1(4):187–99.
35. Azad N, Byszewski A, Sarazin FF, McLean W,
Koziarz P. Hospitalized patients’ preference in the
treatment of insomnia: pharmacological versus
non-pharmacological. Can J Clin Pharmacol 2003;
10(2):89 –92.
36. Espie CA, Inglis SJ, Harvey L. Predicting clinically
signiﬁcant response to cognitive behavior therapy for
chronic insomnia in general medical practice: analysis of outcome data at 12 months posttreatment. J
Consult Clin Psychol 2001;69(1):58 – 66.
37. Aikens JE, Rouse ME. Help-seeking for insomnia
among adult patients in primary care. J Am Board
Fam Pract 2005;18(4):257– 61.
38. Bluestein D, Rutledge CM, Healey AC. Psychosocial
correlates of insomnia severity in primary care. J Am
Board Fam Med 2010;23:204 –11.
39. Morin CM, Beaulieu-Bonneau S, LeBlanc M, et al.
Self-help treatment for insomnia: a randomized controlled trial. Sleep 2005;28(10):1319 –27.
40. Morin CM. Insomnia: psychological assessment and
management. New York: Guilford Press; 1993:104,
205–7.
41. Keenan RA, Wild MR, McArthur I, Espie CA. Children with developmental disabilities and sleep problems: parental beliefs and treatment acceptability.
J Appl Res Intellect Disabil 2007;20:455– 65.
42. Vincent N, Lionberg C. Treatment preference and
patient satisfaction in chronic insomnia. Sleep 2001;
24(4):411–7.
43. SF-36.org. The SF-8 Health Survey. Available at:
http://www.sf-36.org/tools/sf8.shtml. Accessed 24
August 2010.
44. Lewinsohn P M, Seeley JR, Roberts RE, Allen NB.
Center for Epidemiologic Studies Depression Scale
(CES-D) as a screening instrument for depression
among community-residing older adults. Psychol Aging 1997;12:277– 87.

Behavioral Treatments for Insomnia

279

45. Lacks P. Behavioral treatment for persistent insomnia. New York, NY: Pergamon Press; 1987:79.
46. Morin CM. Insomnia: psychological assessment and
management. New York, NY: Guilford Press; 1993.
47. Morin CM, Blais F, Savard J. Are changes in beliefs
and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther
2002;40(7):741–52.
48. Bastien CH, Vallières A, Morin CM. Validation of
the insomnia severity index as an outcome measure
for insomnia research. Sleep Med. 2001;2:297–30.
49. Cohen J. Quantitative Methods in Psychology: A
Power Primer. Psych Bulletin 1992;112(1):155–159.

280 JABFM May–June 2011

Vol. 24 No. 3

50. Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of
a brief version (DBAS-16). Sleep. 2007;30(11):
1547–54.
51. Mezick EJ, Matthews KA, Hall M, Strollo PJ Jr.,
Buysse DJ, Kamarck TW, Owens JF, Reis SE. Inﬂuence of race and socioeconomic status on sleep:
Pittsburgh SleepSCORE project. Psychosom Med.
2008;70(4):410 –16.
52. Epstein D. Treatment preference: applications in
insomnia research: behavioral interventions for insomnia: participant preferences. Commun Nurs Res.
39:163, 2006.

http://www.jabfm.org

